UBS O'Connor’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

UBS O'Connor’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-64,698	Closed	-$3.64M	–	635
2023 Q3	$2.82M	Buy	64,698 +5,000	+8%	+$179K	0.05%	184
2023 Q2	$2.16M	Buy	59,698 +12,448	+26%	+$513K	0.05%	281
2023 Q1	$1.76M	Buy	47,250 +1,250	+3%	+$56.2K	0.04%	343
2022 Q4	$2.08M	Buy	+46,000	New	+$2.98M	0.04%	459

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS O'Connor's MRTX Position: Q4 2023 in Review

UBS O'Connor sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 64,698 shares — an estimated $3.64M sold.

UBS O'Connor first reported a position in MRTX in Q4 2022 and held it in 4 quarters. The position peaked at $2.82M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

UBS O'Connor reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS O'Connor sold 64,698 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $3.64M.
UBS O'Connor first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 4 quarters.
UBS O'Connor's Mirati Therapeutics, Inc. Common Stock position peaked at $2.82M in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.